Since upregulated RIP3 expression is related to disease pathology via either MLKL-dependent necroptotic cell death or altered gene expression under both MLKL-dependent and independent conditions, it ...

The above findings suggest that potent and selective inhibitors of RIPK1 would block RIPK1-dependent pro-inflammatory signaling, including the subsequent activation of RIPK3 and the downstream MLKL ...

The investigational METTL3 RNA methyltransferase inhibitor STC-15 was well tolerated with clinical activity seen across multiple tumor types, according to results from a phase 1 study (NCT05584111) ...

Necrosulfonamide (NSA) is a MLKL inhibitor targets the N-terminal domain of MLKL, and, as a result, blocks the necrotic membrane disruption mediated by MLKL (Sun et al., 2012). Zhou et al. have ...

An MLKL inhibitor blocks diabetes-induced myelin decompaction and NCV decrease. (A) Differential centrifugation of extracts from sural nerves in hMLKL-KI diabetic mice showed that MLKL was inserted ...

Mixed lineage kinase domain‐like (MLKL) is the executioner in the caspase‐independent form of programmed cell death called necroptosis. Receptor‐interacting serine/threonine protein kinase 3 (RIPK3) ...

The 'executioner' protein MLKL kills cells through an inflammatory process called necroptosis. Monobody technology has enabled WEHI researchers to capture different forms of MLKL as it becomes ...

Cells were treated with MLKL (mixed lineage kinase domain-like protein) inhibitor necrosulfonamide (10 µmol/L each) for 1 h before infection. G, 8-oxoguanine (8-OXO, green) was stained in H9c2 rat ...

Cells were treated with MLKL (mixed lineage kinase domain-like protein) inhibitor necrosulfonamide (10 µmol/L each) for 1 h before infection. G, 8-oxoguanine (8-OXO, green) was stained in H9c2 rat ...